FITC Mouse Anti-Human CD52 Antibody (S-R431)
FITC Mouse Anti-Human CD52 Antibody (S-R431)
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD52 |
| Synonyms | CAMPATH-1 antigen; CDw52; Cambridge pathology 1 antigen; Epididymal secretory protein E5; Human epididymis-specific protein 5 (He5); HE5 |
| Location | Cell membrane |
| Accession | P31358 |
| Clone Number | S-R431 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Purification | Protein G |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5 μl per million cells in 100μl volume |
Background
CD52 is a small glycoprotein consisting of 12 amino acids, anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor. It is widely expressed on the surface of various immune cells, including normal and malignant T and B lymphocytes, monocytes, and some epithelial cells. Although its exact biological function remains unclear, CD52 is believed to play roles in T-cell migration, activation, and immune regulation. Importantly, CD52 is the target of alemtuzumab, a humanized monoclonal antibody used to treat diseases like chronic lymphocytic leukemia (CLL) and multiple sclerosis. Alemtuzumab induces cell destruction through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Recent studies also suggest that CD52 may have immunosuppressive effects by binding to the SIGLEC-10 receptor and inhibiting T-cell function.
